Obesity and Dyslipidemia.
Nussbaumerova B, Rosolova H.
Curr Atheroscler Rep. 2023 Dec;25(12):947-955. doi: 10.1007/s11883-023-01167-2. Epub 2023 Nov 18.
Obesity and dyslipidemia.
Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V.
Metabolism. 2019 Mar;92:71-81. doi: 10.1016/j.metabol.2018.11.005. Epub 2018 Nov 14.
Obesity and dyslipidemia in early life: Impact on cardiometabolic risk.
Zeljkovic A, Vekic J, Stefanovic A.
Metabolism. 2024 Jul;156:155919. doi: 10.1016/j.metabol.2024.155919. Epub 2024 Apr 21.
Acanthosis nigricans.
Stuart CA, Driscoll MS, Lundquist KF, Gilkison CR, Shaheb S, Smith MM.
J Basic Clin Physiol Pharmacol. 1998;9(2-4):407-18. doi: 10.1515/JBCPP.1998.9.2-4.407.
Acanthosis nigricans independently predicts hepatic fibrosis in people with type 2 diabetes in North India.
Dutta K, Bhatt SP, Madan S, Ansari IA, Tyagi K, Pandey S, Misra A.
Prim Care Diabetes. 2024 Apr;18(2):224-229. doi: 10.1016/j.pcd.2024.01.003. Epub 2024 Jan 19.
Is Acanthosis Nigricans a reliable indicator for risk of type 2 diabetes?
Jones LH, Ficca M.
J Sch Nurs. 2007 Oct;23(5):247-51. doi: 10.1177/10598405070230050201.
Obesity and atherogenic dyslipidemia.
Bamba V, Rader DJ.
Gastroenterology. 2007 May;132(6):2181-90. doi: 10.1053/j.gastro.2007.03.056.
Acanthosis nigricans: relation with type 2 diabetes mellitus, anthropometric variables, and body mass in Indians.
Grandhe NP, Bhansali A, Dogra S, Kumar B.
Postgrad Med J. 2005 Aug;81(958):541-4. doi: 10.1136/pgmj.2004.028308.
Screening for type 2 diabetes in children with acanthosis nigricans.
Hardin DS.
Diabetes Educ. 2006 Jul-Aug;32(4):547-52. doi: 10.1177/0145721706290436.
Combined dyslipidemia in childhood.
Kavey RE.
J Clin Lipidol. 2015 Sep-Oct;9(5 Suppl):S41-56. doi: 10.1016/j.jacl.2015.06.008. Epub 2015 Jun 17.
